[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ischemic-heart-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ischemic-heart-disease":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,56,0,25,[9,45,71,105,126,178,201,229,259,288,321,344,369,390,412,430,456,482,501,521,541,567,592,621,643],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100623620","long-nagomi-pmcf-study-100623620",false,"NCT07399002","LONG NAGOMI™ PMCF STUDY","Long Coronary Lesions: Safety and Performance of the Ultimaster Nagomi™ Stent in This Setting With a One-to-one Approach -One Lesion, One Stent- LONG NAGOMI™ PMCF STUDY","LONG NAGOMI","Inclusion Criteria:\n\n* Patients who meet ALL inclusion criteria will be included:\n* Patients aged ≥ 18 years AND;\n* Patients who according to standard practice of the hospital are amenable to PCI as indicated and considered adequate according to the European clinical practice guidelines on coronary revascularization AND;\n* Patients with at least one lesion fulfilling the \"long lesion criteria\" suitable for a single stent approach AND;\n* Patients who have been informed of the characteristics of the study and have provided written informed consent AND;\n* Intention to treat all lesions with the Ultimaster Nagomi™ stent\n\nExclusion Criteria:\n\n* Patients must not meet any of the following exclusion criteria:\n* Patients who expressly decline to participate in the study.\n* Pregnant or breastfeeding women.\n* Patients with acute coronary syndrome (ACS) under conditions of cardiogenic shock (Killip class 4).\n* Patients with contraindications or hypersensitivity to sirolimus.\n* Patients with a life expectancy of less than 2 years.\n* Patients in whom any surgery requiring general anesthesia is planned, comorbidity or indication likely necessitating the discontinuation of dual anti-platelet therapy before the recommended duration of dual anti-platelet therapy per the ESC or national guidelines.\n* Patients included in other clinical trials that did not reach the primary objective.","ALL","18 Years",{"count":21,"type":22},1039,"ESTIMATED","12 Months","OBSERVATIONAL","The study is designed as a prospective, multi-center, observational PMCF (post-market clinical follow-up) study of the Ultimaster Nagomi™ \\_stent (lengths of 38, 44 and 50 mm) in the treatment of coronary artery disease according to the indications approved in the CE marking.",[27,28],"Coronary Artery Disease","Ischemic Heart Disease",[30,31],"MDR (Medical Device Regulations)","PMCF (Post-Market Clinical Follow-up)","RECRUITING","2026-06-19",{"date":35,"type":36},"2026-06-23","ACTUAL",{"date":38,"type":36},"2026-02-27",{"date":40,"type":22},"2029-01-01",{"name":42,"class":43},"Fundación EPIC","OTHER",7,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":52,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100582426","ultrathin-strut-sirolimus-eluting-stent-with-bioabsorbable-polymer-in-patients-receiving-chronic-oral-anticoagulation-100582426","NCT06863155","Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation","ACO_FLEX","Inclusion Criteria:\n\nPatients must meet all inclusion criteria:\n\n* Patients with Signed informed consent and\n* Patients with \\>=18 years old and\n* Patients with chronically receiving oral anticoagulation treatment with any type of anticoagulant for any reason and\n* Patients with de novo Coronary artery disease requiring both elective or urgent percutaneous revascularization due to stable coronary artery disease or acute coronary syndrome with or without ST-segment elevation, and in which an ultrathin strut Sirolimus-eluting stent with bioabsorbable polymer has been used\n\nExclusion Criteria:\n\nPatients do not have to meet any exclusion criteria\n\n* Patients treated percutaneously with any type of stent other than the SupraFlex Cruz® in the 6 months prior to the index procedure in which he or she is included.\n* Use in the same procedure or in a scheduled procedure of other stents different from the one evaluated for the treatment of another vessel(s).\n* Patients treatment for restenosis or stent thrombosis.\n* Patients presentation in cardiogenic shock or after cardiorespiratory arrest.\n* Patients with allergy to any of the components of the stent to be used.\n* Patients with impossibility for follow-up.\n* Patients with life expectancy less than 1 year.",{"count":53,"type":22},500,"Patients receiving chronic oral anticoagulation with indication for percutaneous coronary revascularization with stent implantation, and needing for antiplatelet therapy, are at high risk of bleeding. The new generation of ultrathin strut sirolimus-eluting stent with bioabsorbable polymer allow for shorter antiplatelets regimens and could be a good option for this high-bleeding risk patients.",[27,28],[57,58,59,60,61],"Chronic oral anticoagulation","Ultrathin-strut stent","Biodegradable polymer","High-bleeding risk","Percutaneous Coronary Intervention","2026-06-14",{"date":64,"type":36},"2026-06-16",{"date":66,"type":36},"2025-05-06",{"date":68,"type":22},"2029-03-31",{"name":42,"class":43},12,{"id":72,"slug":73,"hasResults":12,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":104},"100642807","qfr-guided-virtual-stenting-for-preprocedural-physiological-optimization-of-percutaneous-coronary-intervention-a-randomized-controlled-trial-100642807","NCT07635407","QFR-Guided Virtual Stenting for Preprocedural Physiological Optimization of Percutaneous Coronary Intervention: A Randomized Controlled Trial","A Multicenter, Prospective, Randomized Controlled Trial of Preprocedural Physiological Optimization of Percutaneous Coronary Intervention Using Coronary Imaging-Physiology Fusion-Based Virtual Stenting Technology","FAVOR-Virtual","Inclusion Criteria:\n\n* Age ≥18 years.\n* Diagnosis of coronary artery disease requiring percutaneous coronary intervention (PCI) according to current clinical practice.\n* Presence of at least one target coronary lesion considered suitable for PCI and evaluable by angiography-derived Quantitative Flow Ratio (QFR).\n* Ability to undergo coronary angiography and PCI. Provision of written informed consent before study participation.\n\nExclusion Criteria:\n\n* Contraindications to PCI or inability to undergo coronary intervention. Severe renal dysfunction or other conditions making angiographic procedures unsuitable.\n* High bleeding risk judged by investigators.\n* Inability to complete follow-up or comply with study procedures.\n* Life expectancy less than 1 year due to non-cardiovascular comorbidities.\n* Participation in another interventional clinical trial that may interfere with study outcomes.\n* Coronary anatomy unsuitable for QFR-based virtual stenting analysis.\n* Any condition judged by investigators to make study participation inappropriate.",{"count":80,"type":22},1472,"INTERVENTIONAL",[83],"NA","Coronary angiography-guided percutaneous coronary intervention (PCI) remains the standard treatment strategy for patients with coronary artery disease; however, suboptimal post-PCI physiological outcomes remain common and are associated with adverse cardiovascular prognosis. Quantitative Flow Ratio (QFR)-based virtual stenting technology enables simulation of post-intervention coronary physiology before PCI and may facilitate individualized optimization of stent implantation strategies.\n\nThis multicenter, prospective, randomized controlled trial aims to evaluate whether preprocedural physiological optimization of PCI using coronary imaging-physiology fusion-based virtual stenting technology improves clinical outcomes compared with conventional angiography-guided PCI. Eligible patients undergoing PCI for coronary artery disease will be randomized in a 1:1 ratio to either virtual stenting-guided PCI optimization or standard angiography-guided PCI.\n\nThe primary endpoint is major adverse cardiovascular events (MACE), defined as a composite of all-cause death, nonfatal myocardial infarction, and ischemia-driven repeat revascularization within 1 year after PCI. Secondary endpoints include post-PCI physiological optimization, cardiovascular death or nonfatal myocardial infarction, repeat revascularization, quality of life, procedural safety, and health economic outcomes.",[27,86,28],"Coronary Stenosis",[61,88,89,90,27,91,92],"Quantitative Flow Ratio","Virtual Stenting","Coronary Physiology","Physiological Optimization","Functional Revascularization","NOT_YET_RECRUITING","2026-06-07",{"date":96,"type":36},"2026-06-09",{"date":98,"type":22},"2026-07-01",{"date":100,"type":22},"2028-12-31",{"name":102,"class":103},"China National Center for Cardiovascular Diseases","OTHER_GOV",1,{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":81,"phases":115,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":123,"locationsCount":104},"100607719","phase-2-exploratory-study-of-adr-002k-for-heart-failure-patients-with-ischemic-heart-disease-who-undergo-cabg-100607719","NCT07192211","Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo CABG","Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo Coronary Artery Bypass Surgery","Inclusion Criteria:\n\n1. Patients clinically diagnosed with chronic heart failure due to ischemic heart disease who undergo CABG\n2. Patients with an LVEF of less than 40% as determined by the cardiac ultrasound at the screening examination.\n3. Others\n\nExclusion Criteria:\n\n1. Patients who have a combination of cardiovascular disease such as severe organic valvular disease.\n2. Patients who have developed acute coronary syndrome within 3 months prior to obtaining consent.\n3. Others","80 Years",{"count":114,"type":22},50,[116],"PHASE2","ADR-002K is administered to heart failure patients with ischemic heart disease who undergo coronary artery bypass surgery (CABG) to investigate its efficacy and safety.",[28],{"date":96,"type":36},{"date":121,"type":36},"2026-04-28",{"date":68,"type":22},{"name":124,"class":125},"Rohto Pharmaceutical Co., Ltd.","INDUSTRY",{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":134,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":137,"conditions":138,"keywords":153,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":177},"100569808","ai-enabled-direct-from-ecg-ejection-fraction-ef-severity-assessment-using-cor-ecg-wearable-monitor-100569808","NCT06699056","AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor","AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Using COR ECG Wearable Monitor","EFACT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Able and eligible to wear a Holter monitor\n\nExclusion Criteria:\n\n* Receiving mechanical respiratory or circulatory support, or renal support therapy, at the time of screening or during Visit #1\n* Any condition that, in the investigator's opinion, could interfere with compliance with the study protocol or pose a safety risk to the participant\n* History of poor tolerance or severe skin reactions to ECG adhesive materials",true,{"count":136,"type":22},2000,"This prospective, multicenter, cluster-randomized controlled study aims to evaluate the accuracy of an investigational artificial intelligence (AI) Software as a Medical Device (SaMD) designed to compute ejection fraction (EF) severity categories based on the American Society of Echocardiography's (ASE) 4-category scale. The software analyzes continuous ECG waveform data acquired by the FDA-cleared Peerbridge COR® ECG Wearable Monitor, an ambulatory patch device designed for use during daily activities. The AI software assists clinicians in cardiac evaluations by estimating EF severity, which reflects how well the heart pumps blood.\n\nIn this study, EF severity determination will be made using 5-minute ECG recordings collected during a 15-minute resting period with participants seated upright. The results will be compared to EF severity obtained from an FDA-cleared, non-contrast transthoracic echocardiogram (TTE) predicate device. This comparison aims to validate the accuracy of the AI software.",[139,140,141,142,143,144,145,28,146,147,148,149,150,151,152],"Ventricular Ejection Fraction","LVF","LV Dysfunction","Atrial Enlargement","Conduction Defect","Heart Failure","Valvular Heart Disease","Cardiotoxicity","Myocardial Infarction","Dilated Cardiomyopathy","HFrEF - Heart Failure With Reduced Ejection Fraction","HFpEF - Heart Failure With Preserved Ejection Fraction","Syncope","Remodeling, Cardiac",[154,155,156,157,158,159,160,141,161,162,163,164,165,166,142,167],"ECG Patch","LVEF","Holter","ECG Wearable","COR","Atrial Conduction","ECG Biomarker","SaMD","Clinical Decision Support","ECG","EF Severity","Ejection Fraction","AI","Electrical Remodeling","2026-05-28",{"date":170,"type":36},"2026-06-01",{"date":172,"type":36},"2024-11-21",{"date":174,"type":22},"2027-11-15",{"name":176,"class":125},"Peerbridge Health, Inc",8,{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":81,"phases":188,"briefSummary":189,"conditions":190,"keywords":192,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":104},"100538683","international-multicenter-project-comparing-radiofrequency-ablation-versus-implantable-defibrillator-after-well-tolerated-ventricular-tachycardia-in-ischemic-heart-disease-with-minimally-impaired-ejection-fraction-100538683","NCT06294028","International Multicenter Project Comparing Radiofrequency Ablation Versus Implantable Defibrillator After Well-tolerated Ventricular Tachycardia in Ischemic Heart Disease With Minimally Impaired Ejection Fraction","VIVA","Inclusion Criteria:\n\n* ischemic heart disease with history of infarction - LVEF\\> 35% (measured by MRI)\n* sustained monomorphic ventricular tachycardia - without history of syncope or cardiac arrest -\n* having signed informed consent\n* affiliated to a social security system\n\nExclusion Criteria:\n\n* transient regressive cause of ventricular tachycardia\n* recent myocardial infarction (\\\u003C2 months)\n* ventricular tachycardia by reentry from branch to branch\n* serious conduction disturbances (with indication of stimulation)\n* contraindication to the implantation of a defibrillator or to the performance of an ablation (life expectancy \\\u003C1 year, relevant comorbidities)\n* pregnancy\n* age \\\u003C18 years\n* Patient under legal protection, guardianship or curatorship","90 Years",{"count":187,"type":22},268,[83],"Evidence for the usefulness of the defibrillator in cases of preserved left ventricular ejection fraction and well-tolerated ventricular tachycardia (without cardiocirculatory arrest or syncope) is lacking, as no previous trials have included such patients. Additionally, sudden death in this particular population is low compared to other subgroups of patients with malignant ventricular arrhythmias.\n\nOn the other hand, numerous recent retrospective data show that ablation of ventricular tachycardia can reduce mortality, and also clearly reduces the number of recurrences in prospective studies.\n\nFinally, a very low rate of sudden death was observed in a multicenter European retrospective study that we conducted, including patients with well-tolerated ventricular tachycardia in structural heart disease with minimally impaired ejection fraction and benefiting from ablation without implantation of defibrillator.",[28,191],"Ventricular Tachycardia",[193],"Ablation",{"date":170,"type":36},{"date":196,"type":36},"2024-06-12",{"date":198,"type":22},"2029-12-31",{"name":200,"class":43},"University Hospital, Toulouse",{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":18,"minAge":209,"maxAge":210,"enrollmentInfo":211,"targetDuration":4,"studyType":81,"phases":213,"briefSummary":214,"conditions":215,"keywords":216,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":228},"100527228","phase-2-single-or-repeated-intravenous-administration-of-umbilical-cord-mesenchymal-stromal-cells-in-ischemic-cardiomyopathy-100527228","NCT06145035","Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy","University of Louisville - 18642 \u002F CATO Study, Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy","CATO","Inclusion Criteria:\n\n1. Be ≥ 21 and ≤ 85 years of age.\n2. Have documented CAD (\\> 70% lesion in at least 1 epicardial vessel) with evidence of myocardial injury, LV dysfunction, and clinical evidence of HF.\n3. Have a \"detectable\" area of myocardial injury defined as ≥ 5% LV involvement (infarct volume) and any subendocardial involvement by MRI.\n4. Have an EF ≤ 40% by MRI.\n5. Be receiving guideline driven medical therapy for HF (beta blockers, diuretics, ACE inhibitors or ARBs, or ARNIs, aldosterone antagonists, hydralazine isosorbide, sodium-glucose transporter 2 inhibitors) ) at stable, maximally tolerated doses for ≥ 1 month prior to consent. \"Stable\" is defined as stable dose with no changes for 30 days after last dose adjustment. For beta blockade \"stable\" is defined as no greater than a 50% reduction in dose or no more than a 100% increase in dose.\n6. Have NYHA class I, II or III symptoms of HF (see Appendix A)\n7. If a female of childbearing potential, be willing to use one form of birth control for the duration of the study and undergo a serum pregnancy test at baseline and within 36 hours prior to infusion\n\nExclusion Criteria:\n\n1. Indication for standard of care surgery (including valve surgery, placement of left ventricular assist device, or imminent heart transplantation), coronary artery bypass grafting (CABG) procedure, and\u002For percutaneous coronary intervention (PCI) for the treatment of ischemic and\u002For valvular heart disease. Subjects who require or undergo PCI should undergo these procedures a minimum of 3 months in advance of randomization. Subjects who require or undergo CABG should undergo these procedures a minimum of 3 months in advance of randomization. In addition, subjects who develop a need for revascularization following enrollment should undergo revascularization without delay. Indication for imminent heart transplantation is defined as a high likelihood of transplant prior to collection of the 12 month study endpoint. Candidates cannot be UNOS 1A or 1B, and they must have documented a low probability of being transplanted.\n2. Severe valvular (any valve) insufficiency and\u002For regurgitation within 12 months of consent\n3. History of ischemic or hemorrhagic stroke within 90 days of consent\n4. Presence of a pacemaker and\u002For implantable cardiac device (ICD) generator with any of the following limitations\u002Fconditions:\n\n   * manufactured before the year 2000\n   * leads implanted \\\u003C 6 weeks prior to consent\n   * non transvenous epicardial or abandoned leads\n   * subcutaneous ICDs (if not MRI compatible)\n   * leadless pacemakers\n   * any other condition that, in the judgment of device trained staff, would deem an MRI contraindicated\n5. Pacemaker dependence with an ICD (Note: pacemaker dependent candidates without an ICD are not excluded)\n6. A cardiac resynchronization therapy (CRT) device implanted less than 3 months prior to consent.\n7. Other MRI contraindications (e.g. patient body habitus incompatible with MRI)\n8. An appropriate ICD firing or anti tachycardia pacing (ATP) for ventricular fibrillation or ventricular tachycardia within 30 days of consent\n9. Ventricular tachycardia ≥ 20 consecutive beats without an ICD within 3 months of consent, or symptomatic Mobitz II or higher degree atrioventricular block without a functioning pacemaker within 3 months of consent\n10. Evidence of active myocarditis\n11. Baseline glomerular filtration rate (eGFR) \\\u003C 35 ml\u002Fmin\u002F1.73m2\n12. Blood glucose levels (HbA1c) \\>10%\n13. Hematologic abnormality evidenced by hematocrit \\\u003C 25%, white blood cell \\\u003C 2,500\u002Ful or platelet count \\\u003C 100,000\u002Ful\n14. Liver dysfunction evidenced by enzymes (AST and ALT) ˃ 3 times the ULN.\n15. HIV and\u002For active HBV or HCV\n16. Known history of anaphylactic reaction to penicillin or streptomycin\n17. Received gene or cell based therapy from any source within the previous 12 months.\n18. History of malignancy within 2 years (i.e., subjects with prior malignancy must be disease free for 2 years), excluding basal cell carcinoma and cervical carcinoma in situ which have been definitively treated.\n19. Condition that limits lifespan to \\\u003C 1 year\n20. History of drug abuse (illegal \"street\" drugs except marijuana, or prescription medications not being used appropriately for a pre-existing medical condition) or alcohol abuse (≥ 5 drinks\u002Fday for ˃ 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 12 months.\n21. Participation in an investigational therapeutic or device trial within 30 days of consent\n22. Cognitive or language barriers that prohibit obtaining informed consent or any study elements\n23. Pregnancy or lactation or plans to become pregnant in the next 12 months.\n24. Any other condition that, in the judgment of the Investigator or Sponsor, would impair enrollment, study product administration, or follow up.","21 Years","85 Years",{"count":212,"type":22},60,[116],"This is a Phase IIA, randomized, double blind, placebo controlled, multicenter study designed to assess the safety, feasibility, and efficacy of umbilical cord derived mesenchymal stromal cells (UC MSCs, stem cells), administered intravenously (IV) as a single dose or repeated doses, in patients with ischemic cardiomyopathy (ICM).",[28],[217,218],"ischemic cardiopathy","UC-MSCs","2026-05-08",{"date":221,"type":36},"2026-05-13",{"date":223,"type":36},"2024-03-04",{"date":225,"type":22},"2028-09-01",{"name":227,"class":43},"Roberto Bolli",3,{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":238,"conditions":239,"keywords":243,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":104},"100638027","ai-enhanced-single-lead-ecg-screening-for-coronary-stenosis-100638027","NCT07579624","AI-Enhanced Single-Lead ECG Screening for Coronary Stenosis","Screening for Significant Coronary Artery Stenosis Using Single-channel Electrocardiogram Analysis With Artificial Intelligence Elements","Inclusion Criteria:\n\n* Presence of written informed consent from the patient to participate in the study.\n* Age 18 years and older.\n* Outpatient visit and\u002For hospitalization at the research center with coronary visualization performed.\n\nNon-inclusion criteria:\n\n* Absence of sufficient data on coronary anatomy and stenosis significance.\n* Any conditions impairing the quality of single-channel ECG recording (Parkinson's disease, essential tremor, and others).\n* Absence of written informed consent from the patient to participate in the study.\n\nExclusion Criteria:\n\n* Patient's unwillingness to continue participation in the study.\n* Inability to perform full analysis of single-channel ECG digital characteristics.\n* Refusal of coronary visualization methods for any reason.",{"count":237,"type":22},400,"It is a prospective, controlled, single-center, non-randomized, observational study. Two patient groups are planned for inclusion: the first - 200 patients with significant coronary artery stenosis confirmed by coronary angiography (CAG) or multislice computed tomography (MSCT) results; the second - a control group consisting of 200 patients without significant stenosis according to CAG or MSCT data.\n\nAll study subjects will have a date of coronary artery imaging via CAG or MSCT with assessment of myocardial perfusion.\n\nStress echocardiography tests or fractional flow reserve (FFR) assessment will be conducted as indicated.\n\nAll patients included in the study will undergo ECG recording within 1 month before or after CAG or MSCT in standard lead I for 1 minute, followed by spectral analysis of the obtained data, which will be stored at the remote monitoring center of Sechenov University without being linked to the personal data of patients. A spectral analysis of the electrocardiogram will be performed using a continuous wavelet transform.\n\nThe result of this study will be the identification of ECG parameters that correlate with significant coronary artery stenosis.",[28,240,241,242],"Coronary Artery Stenosis","Stable Angina Pectoris","Acute Coronary Syndromes",[244,28,245,246,247,248,249],"coronary","Single-Channel ECG","Artificial Intelligence","AI-Enhanced Screening","Non-Invasive Diagnostics","Angina","2026-05-06",{"date":252,"type":36},"2026-05-12",{"date":254,"type":22},"2026-05-01",{"date":256,"type":22},"2027-12-01",{"name":258,"class":43},"I.M. Sechenov First Moscow State Medical University",{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":134,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":267,"targetDuration":269,"studyType":24,"phases":4,"briefSummary":270,"conditions":271,"keywords":279,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":281,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":104},"100489526","development-of-circ-technologies-100489526","NCT05654272","Development of CIRC Technologies","Development of Cardiovascular Innovation Research Technologies","CIRC","Inclusion Criteria:\n\n* Age ≥ 18 years of age\n* Provision of written informed consent\n* If not healthy volunteer, must be diagnosed with cardiovascular disease\n\nExclusion Criteria:\n\n* Vulnerable populations will be excluded from this study including Prisoners\n* Other contraindications to CMR imaging to be determined by standard MRI protocols\n* Decisionally impaired (e.g., dementia or cognitive disability)",{"count":268,"type":22},1000,"20 Years","Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Moreover, the intrinsic advantage of MRI's lack of exposure to ionizing radiation is particularly beneficial. At the same time, blood work can be very useful in early detection of certain cardiomyopathy, such as amyloid. However, there is a lack of agreement of on which markers are the most sensitive. This multi-study will allow us the unique opportunity to form a more comprehensive understanding for various cardiovascular diseases.\n\nOur team has developed novel cardiac MRI techniques that leverages endogenous tissue properties to reveal a milieu of deep tissue phenotypes including myocardial inflammation, fibrosis, metabolism, and microstructural defects. Among these phenotypes, myocardial microstructure has proven to be most sensitive to early myocardial tissue damage and is predictive of myocardial regeneration. In this study, the investigators aim to further study the importance of cardiac microstructure revealed by MRI in patient and healthy population and compare this novel technology with conventional clinical biomarkers.",[272,144,28,273,145,274,275,276,277,278],"Cardiovascular Diseases","Non-ischemic Cardiomyopathy","Metabolic Cardiomyopathy","Congenital Heart Disease","Aortic Diseases","Atrial Fibrillation","Ventricular Fibrillation",[280],"MRI",{"date":219,"type":36},{"date":283,"type":36},"2022-09-09",{"date":285,"type":22},"2042-09-09",{"name":287,"class":43},"The Cleveland Clinic",{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":134,"sex":18,"minAge":19,"maxAge":295,"enrollmentInfo":296,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":104},"100599366","routine-validation-and-reproducibility-testing-of-laboratory-assays-and-research-techniques-used-for-endocrine-cardiometabolic-and-musculoskeletal-disorder-research-vald-100599366","NCT07083557","Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)","VALD","Inclusion Criteria:\n\n* ≥18 and ≤100 years of age\n* body mass index ≥16.0 and ≤60 kg\u002Fm2\n\nExclusion Criteria:\n\n* \\\u003C18 and \\>100 years of age\n* body mass index \\\u003C16.0 or \\>60 kg\u002Fm2\n* allergies, intolerances, or dietary restrictions to meal ingredients, vegans or vegetarians\n* use of medications or dietary supplements (e.g., anti-inflammatories, immune modulators, etc) that could interfere with the particular assay\u002Ftechniques being evaluated\n* engaged in regular structured exercise \\>150 min per week unless needed for validation of the assay\u002Ftechnique being evaluated\n* significant organ system dysfunction or diseases, except those that are sought for validation of the assay\u002Ftechnique being evaluated\n* alcohol use disorder as defined by the National Institute of Alcohol Abuse and Alcoholism or use of controlled substances unless alcohol use disorder is required for validation of the assay\u002Ftechnique being evaluated\n* pregnant women, persons who smoke, prisoners, and inability to grant voluntary informed consent.","100 Years",{"count":297,"type":22},100,"The purpose of this research study is to validate (check the accuracy of) laboratory assays, intravenous catheter insertion, and equipment or devices and their reproducibility, which is necessary to perform high quality research on chronic diseases, nutrition, and metabolism (the process by which a substance is handled in the body) at the University of Missouri. As technology changes and uses new testing methods, it is necessary to compare results from old tests, equipment and devices and new tests, equipment, or devices and the reproducibility of these measurements to make sure the results are accurate. Reproducibility means performing the same test more than once to see if the same results can be achieved each time. This study will look at the validation and reproducibility of tests and laboratory assays in participants who are healthy or affected by relevant endocrine, cardiometabolic, and musculoskeletal disorders.",[300,301,302,144,303,304,305,306,307,28,308,309,310,311],"Obesity and Obesity-related Medical Conditions","Diabetes","Atherosclerotic Disease","MASH","Sarcopenia","Osteoporosis","Hyperparathyroidism","Hypoparathyroidism","Cystic Fibrosis (CF)","Chronic Kidney Disease(CKD)","Osteopenia","Cachexia","2026-05-05",{"date":314,"type":36},"2026-05-07",{"date":316,"type":22},"2027-01-01",{"date":318,"type":22},"2030-07-01",{"name":320,"class":43},"Bettina Mittendorfer",{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":331,"conditions":332,"keywords":334,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":343},"100492944","coroflex-isar-neo-pmcf-study-100492944","NCT05698732","Coroflex® ISAR NEO PMCF Study","Coroflex® ISAR NEO Coronary Stent System Post-Market Clinical Follow-up Study","rEPIC07","Inclusion Criteria:\n\nCoroflex® ISAR NEO is intended to be used for\n\n* Patients must be at least 18 years of age AND\n* The patient must fulfill the standard recommendations for Percutaneous Coronary Intervention (PCI) based on the last European Society of Cardiology (ESC) recommendations within his\u002F her regular treatment or that the use of the product has already been decided within the regular planning of the patient's treatment AND\n* Patients with Novo lesion length 2-4 mm AND\n* Informed consent signed\n\nExclusion Criteria:\n\n* Patients with express refusal by the patient to participate in the study.\n* Patients pregnant women and lactating women.\n* Patients with acute coronary syndrome (ACS) in a situation of cardiogenic shock (Killip 4).\n* Patients in whom anti-platelet and\u002For anti-coagulation therapy is contraindicated\n* Patients with lesions, that possibly can not be treated successfully with Percutaneous transluminal Coronary Angioplasty (PTCA) or stent implantation\n* Patients with known sensitivity to Sirolimus, the carrier Probucol, the procedural co-medication or the alloying component of the stent\n* Patients with known sensitivity to contrast agents who cannot be premedicated.\n* Patients with contraindications or hypersensitivity to sirolimus\n* Patients with a life expectancy of less than 2 years\n* Patients included in other clinical trials",{"count":330,"type":22},3000,"International, Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Coroflex® ISAR NEO coronary stent system to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Coroflex® ISAR NEO coronary stent system sirolimus eluting stent.",[333,28],"Coronary Artery Disease (CAD)",[30,31,335],"Drug Eluting Stent","2026-04-30",{"date":254,"type":36},{"date":339,"type":36},"2023-08-04",{"date":341,"type":22},"2027-02-01",{"name":42,"class":43},22,{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":353,"conditions":354,"keywords":357,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":104},"100467324","association-between-radial-artery-intervention-and-development-of-neuropathy-in-the-hand---a-prospective-study-100467324","NCT05365282","Association Between Radial Artery Intervention and Development of Neuropathy in the Hand - A Prospective Study","Association Between Radial Artery Intervention and Development of Neuropathy in the Hand - A Prospective Study - The ACCESS IV Study","ACCESS-IV","Inclusion Criteria:\n\n* The patient must be able to give informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Negative Barbeau test",{"count":237,"type":22},"Evaluation of potential nerve damage after radial CAG\u002FPCI.",[28,355,356],"Nerve Injury","Carpal Tunnel Syndrome",[358,28,359],"Transradial access","Hand Dysfunction","2026-04-22",{"date":362,"type":36},"2026-04-23",{"date":364,"type":36},"2024-01-01",{"date":366,"type":22},"2028-12-01",{"name":368,"class":43},"Aarhus University Hospital Skejby",{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":377,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":379,"conditions":380,"keywords":381,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":388,"locationsCount":389},"100499836","sequent-extended-study-100499836","NCT05788432","Sequent Extended Study","Sequent Please Neo Extended Post-Market Clinical Follow-up Study","rEpic06","Inclusion Criteria:\n\n* Patients treated with Sequent please neo according to routine hospital practice and following instruction for use.\n* Informed Consent Signed.\n\nExclusion Criteria:\n\n* Patient life expectancy less than 12 months.\n* Contraindication for antiplatelet therapy.\n* Not meet inclusion criteria.",{"count":378,"type":22},2028,"Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Sequent Please Neo to meet EU Medical Device regulation (MDR) requirements in all the consecutive patients treated with Sequent Please Neo.",[27,28],[30,31,382],"Paclitaxel eluting coronary balloon dilatation catheter","2026-04-21",{"date":360,"type":36},{"date":386,"type":36},"2023-03-28",{"date":98,"type":22},{"name":42,"class":43},27,{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":104},"100616676","a-study-of-deep-learning-for-echo-analysis-tracking-and-evaluation-100616676","NCT07308704","A Study Of Deep Learning For Echo Analysis, Tracking, And Evaluation","DELINEATE-Deploy: Deep Learning for Echo Analysis, Tracking, and Evaluation - Prospective Deployment Platform IRB","Inclusion criteria:\n\n* Genetic cardiomyopathy arm: Clinicians who order, perform, and interpret echocardiograms and act on echocardiogram results, including both physicians and allied health staff taking care of patients aged ≥18 years who are undergoing a comprehensive TTE at a participating Mayo Clinic site with AI-Echo analysis indicating high risk for a genetic cardiomyopathy. A high-risk score will be defined by a specific threshold determined in model development to maximize sensitivity while maintaining an adequate positive predictive value to support clinical deployment\n* Ischemic cardiomyopathy arm: Clinicians who order, perform, and interpret echocardiograms and act on echocardiogram results, including both physicians and allied health staff taking care of patients aged ≥18 years who are undergoing a comprehensive TTE with AI-Echo analysis indicating high risk for ischemic cardiomyopathy. A high-risk score will be defined by a specific threshold determined in model development to maximize sensitivity while maintaining an adequate positive predictive value to support clinical deployment.\n* Cardiac amyloidosis arm: Clinicians who order, perform, and interpret echocardiograms and act on echocardiogram results, including both physicians and allied health staff taking care of patients aged ≥18 years who are undergoing a comprehensive TTE with AI-Echo analysis indicating high risk for cardiac amyloidosis. A high-risk score will be defined by a specific threshold determined in model development to maximize sensitivity while maintaining an adequate positive predictive value to support clinical deployment.\n* Hypertrophic cardiomyopathy (HCM) arm: Clinicians who order, perform, and interpret echocardiograms and act on echocardiogram results, including both physicians and allied health staff caring for patients aged ≥18 years who are undergoing a comprehensive TTE at a participating Mayo Clinic site, with AI-Echo analysis indicating high risk for HCM. A high-risk score will be defined by a specific threshold determined during model development to maximize sensitivity while maintaining adequate positive predictive value for clinical deployment.\n\nExclusion criteria:\n\n* Genetic cardiomyopathy arm: Studies performed within the past 2 years at a Mayo site or in those patients with known or suspected diagnosis of genetic cardiomyopathy under evaluation, on hospice care, or who have an expected non-cardiac life expectancy \\\u003C1 year, and patients who have opted out of institutional and state research authorizations.\n* Ischemic cardiomyopathy arm: Studies performed within the past 2 years at a Mayo site or in those patients with known CAD; prior myocardial infarction; revascularization with PCI or CABG; ischemic testing within the past 12 months; hospice care or expected non-cardiac life expectancy \\\u003C1 year, and patients who have opted out of institutional and state research authorizations.\n* Cardiac amyloidosis arm: Studies performed within the past 2 years at a Mayo site or in those patients with prior amyloid-specific testing (e.g., technetium pyrophosphate scan, cardiac MRI with late gadolinium enhancement suggestive of amyloid) or biopsy-proven systemic amyloidosis, on hospice care, or have expected non-cardiac life expectancy \\\u003C1 year, and patients who have opted out of institutional and state research authorizations.\n* Hypertrophic cardiomyopathy (HCM) arm: Studies performed within the past 2 years at a Mayo site or patients with a known diagnosis of HCM documented in the medical record prior to the index TTE, prior septal reduction therapy (surgical myectomy or alcohol septal ablation), or patients on hospice care or with an expected non-cardiac life expectancy \\\u003C1 year, and patients who have opted out of institutional and state research authorizations.",{"count":398,"type":22},10040000,"The purpose of this study is to deploy and evaluate informational AI-Echo algorithms that assist echo clinicians in interpreting core echocardiographic parameters (e.g., LV\u002FRV size and function, valvular disease severity) and stratifying disease progression risk. The primary outcome is clinician usability, interpretive consistency, and workflow integration. Second, we will conduct a pragmatic, stepped-wedge clinical trial with multiple arms evaluating diagnostic AI-Echo algorithms designed to identify specific cardiovascular diseases- such as genetic cardiomyopathy, ischemic heart disease, and cardiac amyloidosis-and assess whether AI deployment increases diagnostic testing and shortens time to diagnosis. Trials will be conducted using EHR-based notification systems with cluster-level randomization.",[401,28,402],"Cardiomyopathy","Cardiac Amyloidosis","2026-04-15",{"date":405,"type":36},"2026-04-16",{"date":407,"type":36},"2026-02-26",{"date":409,"type":22},"2028-02",{"name":411,"class":43},"Mayo Clinic",{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":134,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":419,"conditions":420,"keywords":421,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":4},"100599224","longitudinal-validation-of-circ-technologies-100599224","NCT07081711","Longitudinal Validation of CIRC Technologies","Inclusion Criteria:\n\n* Age ≥ 18 years of age\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Vulnerable populations will be excluded from this study including Prisoners\n* Other contraindications to CMR imaging to be determined by standard MRI protocols\n* Decisionally impaired (e.g., dementia or cognitive disability)",{"count":268,"type":22},"Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Moreover, the intrinsic advantage of MRI's lack of exposure to ionizing radiation is particularly beneficial. At the same time, blood work can be very useful in early detection of certain cardiomyopathy, such as amyloid. However, there is a lack of agreement of on which markers are the most sensitive. This multi-study will allow the unique opportunity to form a more comprehensive understanding for various cardiovascular diseases.\n\nThe study team has developed novel cardiac MRI techniques that leverages endogenous tissue properties to reveal a milieu of deep tissue phenotypes including myocardial inflammation, fibrosis, metabolism, and microstructural defects. Among these phenotypes, myocardial microstructure has proven to be most sensitive to early myocardial tissue damage and is predictive of myocardial regeneration. In this study, the investigators aim to further study the importance of cardiac microstructure revealed by MRI in patient and healthy population and compare this novel technology with conventional clinical biomarkers.",[272,144,28,273,145,274,275,276,277,278],[280],"2026-03-19",{"date":424,"type":36},"2026-03-23",{"date":426,"type":22},"2026-04",{"date":428,"type":22},"2037-08",{"name":287,"class":43},{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":434,"acronym":435,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":81,"phases":438,"briefSummary":439,"conditions":440,"keywords":442,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":104},"100589199","efficacy-of-carbohydrate-loading-in-diabetic-type-2-patients-undergoing-cabg-surgery-on-cpb-100589199","NCT06951308","Efficacy of Carbohydrate Loading in Diabetic Type 2 Patients Undergoing CABG Surgery on CPB","CLDM-CABG","Inclusion Criteria:\n\nAll diabetic type 2 patients undergoing isolated on-pump coronary artery bypass surgery.\n\nExclusion Criteria:\n\n* Missing data.\n* Patients outside the study period.\n* Patients undergoing other cardiac surgeries.\n* Patients diagnosed with type 1 diabetes mellitus.",{"count":114,"type":22},[83],"Enhanced recovery after surgery protocols aim to optimize perioperative care and improve surgical outcomes. Preoperative carbohydrate loading has demonstrated benefits in reducing insulin resistance and improving patient outcomes. While non-diabetic patients benefit from this approach, its efficacy in diabetic type 2 patients undergoing CABG remains less understood. This study aims to address this gab by evaluating the physiological and clinical outcomes for carbohydrate loading in this specific population.",[441,28],"Heart Surgery",[443,444,445,446,447],"Enhanced recovery program","carbohydrate loading","coronary artery bypass grafting","heart surgery","postoperative recovery","2026-03-17",{"date":422,"type":36},{"date":451,"type":36},"2025-04-01",{"date":453,"type":22},"2026-12-31",{"name":455,"class":43},"Damascus University",{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":463,"targetDuration":464,"studyType":24,"phases":4,"briefSummary":465,"conditions":466,"keywords":468,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":104},"100448806","imaging-and-physiologic-evaluation-of-coronary-artery-disease-100448806","NCT05124249","Imaging and Physiologic Evaluation of Coronary Artery Disease","Imaging and Physiologic Evaluation of Coronary Artery Disease: a Prospective Registry Study (IP-CAD)","Inclusion Criteria:\n\n* Subject must be at least 18 years of age\n* Subjects who suspected ischemic heart disease and underwent ICA.\n* Subjects who were performed intravascular imaging or invasive physiologic assessment\n\nExclusion Criteria:\n\n* Subject with Age \\\u003C18 years\n* Pregnant women",{"count":136,"type":22},"3 Years","To evaluate the long-term clinical outcomes and prognostic factors in patients with coronary artery disease (CAD) undergoing invasive coronary angiography (ICA), intravascular imaging, or invasive physiologic assessment.",[28,467],"Atherosclerosis",[61,469,470,471,472],"Intravascular Imaging","Intravascular Ultrasound","Optical Coherence Tomography","Fractional flow reserve","2026-03-16",{"date":475,"type":36},"2026-03-18",{"date":477,"type":36},"2021-11-01",{"date":479,"type":22},"2030-12-31",{"name":481,"class":43},"Chonnam National University Hospital",{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":489,"enrollmentInfo":490,"targetDuration":4,"studyType":81,"phases":491,"briefSummary":492,"conditions":493,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":499,"locationsCount":104},"100629719","phase-2-chaigui-longmu-ejiao-paste-for-ischemic-heart-disease-100629719","NCT07478328","Chaigui Longmu Ejiao Paste for Ischemic Heart Disease","A Randomized, Double-Blind Clinical Trial of Chaigui Longmu Ejiao Paste in the Treatment of Ischemic Heart Disease With Internal and External Controls","Inclusion Criteria:\n\n1. Age 18-75 years, both sexes eligible;\n2. Meets the diagnostic criteria for stable angina pectoris in ischemic heart disease (IHD), with stable condition for ≥4 weeks;\n3. Has received standard Western medical treatment (including but not limited to antiplatelet agents, lipid-modifying\u002Fstabilizing plaque therapy, β-blockers, etc.) for at least 4 weeks, with stable dosages;\n4. Meets the Traditional Chinese Medicine (TCM) syndrome diagnostic criteria of \"thoracic yang deficiency with heart vessel stasis\" (or \"chest yang insufficiency with heart meridian blood stasis\"), with primary symptoms: chest oppression\u002Fpain, palpitations; at least 2 secondary symptoms: insomnia, aversion to cold, spontaneous sweating, irritability or restlessness; supported by tongue and pulse findings;\n5. Has signed the informed consent form and is willing to participate voluntarily in the study.\n\nExclusion Criteria:\n\n1. Acute coronary syndrome or patients requiring emergency revascularization;\n2. Use of traditional Chinese medicine (TCM) or Chinese patent medicines with therapeutic effects on ischemic heart disease within the past 2 weeks;\n3. Poorly controlled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg after treatment);\n4. Severe heart failure (NYHA functional class IV), uncontrolled malignant arrhythmias, cardiogenic shock; severe cerebrovascular diseases; active or recurrent digestive system ulcers or other diseases with bleeding risk; other severe digestive system diseases; complicated with malignant tumors, hematological disorders, or other severe or progressive systemic diseases; complicated with other mental disorders that render the patient unable or unwilling to cooperate;\n5. Severe hepatic or renal impairment (ALT\u002FAST \\> 3 × upper limit of normal, or creatinine \\> 1.5 × upper limit of normal);\n6. Known allergy to any component of the study formula;\n7. Women who are pregnant, lactating, or planning pregnancy;\n8. Patients who have participated in other clinical trials within the past 3 months;\n9. Patients deemed by the investigator to be unsuitable for participation in the clinical trial.","75 Years",{"count":212,"type":22},[116],"This study explores whether Chaigui Longmu Ejiao Paste can reduce the average weekly number of angina attacks in patients with ischemic heart disease after 8 weeks of treatment, using Chaigui Longmu Paste without Ejiao as a parallel control and incorporating a synthesized external control.",[28],"2026-03-13",{"date":448,"type":36},{"date":497,"type":22},"2026-03-08",{"date":100,"type":22},{"name":500,"class":43},"Longhua Hospital",{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":185,"enrollmentInfo":508,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":510,"conditions":511,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":104},"100520280","hyperpolarized-mrsi-in-ischemic-heart-disease-a-metabolic-investigation-of-the-heart-muscle-100520280","NCT06054516","Hyperpolarized MRSI in Ischemic Heart Disease: A Metabolic Investigation of the Heart Muscle","Hyperpolarized MRSI in Ischemic Heart Disease: Metabolic Profiling of the Myocardium","Inclusion Criteria:\n\n* Chronic heart failure\n* \\>18 years of age\n* Left ventricular Ejection Fraction (LVEF) of 10 - 60 %\n* Adequate hematologic and organ function.\n* Women who are not postmenopausal or surgically sterile must have a negative serum or urine pregnancy test performed at time of inclusion in the study.\n* Safe and highly effective contraception must be used throughout the study meaning either hormonal anti-conception or an anti-fertility intrauterine device. If the partner is non fertile or the patient has no sexual activities, this is also accepted.\n* Non-insulin dependent Diabetes mellitus is allowed\n* Danish speaking\n* Able and willing to comply after informed consent\n* Ischemic heart disease and referral to viability testing at the Department of Clinical Physiology and Nuclear Medicine at Aarhus University Hospital.\n\nExclusion Criteria:\n\n* Not able or willing to receive heart failure therapy\n* Patients not willing to participate\n* Uncontrolled serious medical condition, such as uncontrolled heart disease, uncontrolled diabetes, intestinal obstruction, uncontrolled hypertension, or recent cerebral ischemia\n* Estimated Glomerular Filtration Rate (eGFR) \\\u003C30 mL\u002Fmin\n* Insulin dependent Diabetes Mellitus\n* Intolerance to Pyruvate",{"count":509,"type":22},15,"This study aims to investigate the potential of using hyperpolarized \\[1-13C\\]-pyruvate magnetic resonance imaging (MRI) to assess metabolic alterations in patients with ischemic heart disease (IHD). Altered myocardial metabolism is recognized as a crucial factor in heart failure and IHD, and modulating cardiac metabolism offers a new approach to treatment. However, current diagnostic modalities use ionizing radiation and have shown limited prognostic value.\n\nHyperpolarization through dynamic nuclear polarization (DNP) enables highly sensitive in vivo detection of metabolic processes. Hyperpolarized \\[1-13C\\]-pyruvate allows visualization of glycolysis-related metabolism, providing insights into the breakdown of glucose and its derivatives. By using this technique, the study aims to differentiate viable from non-viable myocardium in patients with IHD.\n\nThe objectives include implementing hyperpolarized \\[1-13C\\]-pyruvate cardiac MRI to image metabolic flux in the human heart and investigating the potential of this method to distinguish viable from non-viable myocardium in patients with IHD. The study endpoints involve assessing metabolic flux through the pyruvate dehydrogenase complex (PDC) and analyzing ratios of different metabolites, which can indicate the extent of pyruvate oxidation and lactate production.\n\nA cross-sectional study design involving patients with CHF and ischemic heart disease will be used. Patients will undergo hyperpolarized \\[1-13C\\]-pyruvate MRI, PET imaging, late gadolinium enhancement (LGE) MRI, and cardiac magnetic resonance imaging (CMR). The study will compare \\[1-13C\\]-pyruvate MRI findings with PET results, allowing for a correlation between metabolic data and traditional imaging techniques. This innovative approach could provide valuable insights into the metabolic changes associated with ischemic heart disease",[28],"2026-03-04",{"date":514,"type":36},"2026-03-06",{"date":516,"type":36},"2023-10-13",{"date":518,"type":22},"2027-01-31",{"name":520,"class":43},"Henrik Wiggers",{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":527,"eligibilityCriteria":528,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":529,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":530,"conditions":531,"keywords":532,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":104},"100564590","essential-pro-study--repic04e-hk--100564590","NCT06631157","Essential Pro Study ( rEPIC04E-HK )","Essential Pro Post-Market Clinical Follow-up Study","rEPIC04E-HK","Inclusion Criteria:\n\n* Patient treated with Essential Pro according to routine hospital practice and following instructions for use\n* Informed consent signed\n\nExclusion Criteria:\n\n* Not meet inclusion criteria",{"count":297,"type":22},"Single center, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Essential Pro to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Essential Pro.",[27,28],[30,31,382],"2026-02-12",{"date":535,"type":36},"2026-02-17",{"date":537,"type":36},"2025-05-15",{"date":539,"type":22},"2026-11-01",{"name":42,"class":43},{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":547,"eligibilityCriteria":548,"healthyVolunteers":12,"sex":18,"minAge":549,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":81,"phases":552,"briefSummary":553,"conditions":554,"keywords":555,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":104},"100491668","impact-of-dynamic-coronary-roadmap-system-for-guidance-of-instantaneous-wave-free-ratio-or-fractional-flow-reserve-100491668","NCT05682118","Impact of Dynamic CoROnary RoADmap System for Guidance of Instantaneous Wave-Free Ratio or Fractional Flow Reserve","Impact of Dynamic CoROnary RoADmap System for Guidance of Instantaneous Wave-Free Ratio or Fractional Flow Reserve: A Single-Center, Randomized Study (ROAD-IFR Trial)","ROAD-IFR","Inclusion Criteria:\n\n1. Patients aged 19 years or older\n2. Patients with stable angina, including asymptomatic ischemic heart disease, who have 50-90% stenosis of the causative vessel by coronary angiography\n3. Acute coronary syndrome patients with multivessel disease and 50-90% stenosis of non-caused vessels that did not cause acute coronary syndrome\n4. Patients who voluntarily decided to participate in this study and gave written consent to the subject consent form\n\nExclusion Criteria:\n\n1. Patients with acute coronary syndrome and single vessel disease\n2. Patients who have undergone previous coronary artery bypass grafting\n3. Poor coronary blood flow (TIMI grade ≤ 2)\n4. If life expectancy is less than one year\n5. Women who are pregnant or wish to become pregnant","19 Years",{"count":551,"type":22},226,[83],"In patients with 50-90% stenosis of the coronary artery, the coronary roadmap (dynamic roadmap) is performed when the conventional fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) are performed. coronary roadmap system) to confirm the effectiveness of the function.",[28],[556,557],"iFR\u002FFFR","Roadmap","2026-02-08",{"date":560,"type":36},"2026-02-11",{"date":562,"type":36},"2023-07-31",{"date":564,"type":22},"2026-11-27",{"name":566,"class":43},"Yonsei University",{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":573,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":575,"targetDuration":4,"studyType":81,"phases":577,"briefSummary":578,"conditions":579,"keywords":581,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":590,"locationsCount":591},"100485283","treatment-of-functionally-non-significant-vulnerable-plaques-in-patients-with-multivessel-st-elevation-myocardial-infarction-the-vulnerable-trial-100485283","NCT05599061","Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial","Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Randomized Trial","VULNERABLE","Inclusion Criteria:\n\n* Patients \\> 18 years.\n* Successful revascularization of the culprit lesion in patients undergoing coronary angiography due to ST-segment elevation (\\> 1mm in \\> 2 contiguous leads, new left bundle branch block, or true posterior MI with ST depression of \\>1mm in \\>2 contiguous anterior leads) in the first 72 hours of the symptom's onset.\n* Multivessel coronary disease with non-culprit lesions located in different vessels than the culprit lesion and ranging from 40 to 69% of DS (visual estimated diameter stenosis ) by visual estimate planned for FFR-guided revascularization in staged procedure (\\>24 hours and \\\u003C60 days after PCI of the culprit lesion).\n* Non-culprit lesions should be suitable for functional assessment with pressure wire and OCT catheter and should be suitable to be treated with a single 2.0 to 4.5 mm EES (everolimus-eluting stent ).\n* Subject agrees to not participate in any other clinical trial study for a period of 4 years following the inclusion in the study.\n* Informed consent signed.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Female of childbearing potential (age \\\u003C50 years and last menstruation within the last 12 months), who did not undergo tubal ligation, ovariectomy or hysterectomy.\n* Known intolerance to aspirin, heparin, everolimus, contrast material.\n* Unresolved mechanical complication or cardiogenic shock at the staged procedure.\n* Non-culprit study lesions located in the left main coronary artery or in coronary vessels with prior coronary revascularization (PCI or by-pass) or with distal vessel occlusion.\n* Patients with long, bifurcated, severely angulated or severely calcified non-culprit study lesions non suitable to be treated with a single EES implantation.\n* Asthma or known history of bronchial hyper-reactivity.\n* Chronic renal dysfunction with creatinine clearance \\\u003C 45 ml\u002Fmin.\n* Severe comorbidities that in the opinion of the local investigators determine the patient's life expectancy \\\u003C 4 years.\n* Subject is currently participating in another clinical trial that has not yet completed its primary endpoint.",{"count":576,"type":22},600,[83],"The study aims to compare a preventive percutaneous coronary intervention (PCI) plus optimal medical treatment (OMT) strategy vs. OMT for treatment of non-functionally significant non-culprit lesions presenting with optical coherence tomography (OCT) findings indicative of vulnerable plaque, in patients with ST-elevation myocardial infarction (STEMI) and multivessel disease.",[27,580,28],"Coronary Disease",[582,471,583],"Vulnerable Plaque","Fractional Flow Reserve and ST-elevation Myocardial Infarction","2026-01-27",{"date":586,"type":36},"2026-01-29",{"date":588,"type":36},"2023-01-30",{"date":366,"type":22},{"name":42,"class":43},49,{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":598,"eligibilityCriteria":599,"healthyVolunteers":12,"sex":18,"minAge":269,"maxAge":112,"enrollmentInfo":600,"targetDuration":4,"studyType":81,"phases":602,"briefSummary":604,"conditions":605,"keywords":608,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":612,"lastUpdatePostDateStruct":613,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":4},"100619636","phase-1-endocardial-delivery-for-myocardial-regeneration-using-allogeneic-ipsc-derived-cardiomyocyte-spheroids-for-hf-with-systolic-dysfunction-emerald-study-100619636","NCT07347197","Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study)","A Phase I\u002FII Study of Endocardial Delivery for Myocardial Regeneration Using Human Induced Pluripotent Stem (iPS) Cell-derived Cardiomyocyte Spheroids for Heart Failure Reduced Ejection Fraction","EMERALD","Inclusion Criteria:\n\n* Patients with resting left ventricular ejection fraction (LVEF) ≦40% based on institutional assessment on screening echocardiographic assessment\n* New York Heart Association (NYHA) cardiac function classification of grade II or III at screening\n* Other Criteria apply, please contact the investigator\n\nExclusion Criteria:\n\n* Patients with cardiac devices such as pacemakers, implantable cardioverter defibrillators (ICDs), or cardiac resuscitation-enabled implantable cardioverter defibrillators (CRT-Ds)\n* Patients with heart failure due to the primary disease hypertrophic cardiomyopathy (including the dilated phase), restrictive cardiomyopathy, amyloidosis, takotsubo cardiomyopathy, congenital heart disease, cardiac sarcoidosis, or constrictive pericarditis\n* Other Criteria apply, please contact the investigator",{"count":601,"type":22},14,[603,116],"PHASE1","The purpose of this clinical study is to evaluate the safety and efficacy of endocardial delivery of HS-001 CS into severe heart failure patients with reduced ejection fraction for 26 weeks after transplantation.",[144,606,28,607],"Ischemic Heart Failure","Dilated Cardiomyopathy (DCM)",[144,609,28,607,610,611],"Ischemic heart failure","iPSC","cell therapy","2026-01-08",{"date":614,"type":36},"2026-01-16",{"date":616,"type":22},"2026-01-01",{"date":618,"type":22},"2030-01-31",{"name":620,"class":125},"Heartseed Inc.",{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":626,"acronym":627,"eligibilityCriteria":628,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":629,"targetDuration":4,"studyType":81,"phases":631,"briefSummary":632,"conditions":633,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":389},"100328992","ischemia-cto-trial---revascularisation-or-optimal-medical-therapy-of-cto-100328992","NCT03563417","ISCHEMIA-CTO Trial - Revascularisation or Optimal Medical Therapy of CTO","International Randomized Trial on the Effect of Revascularization or Optimal Medical Therapy of Chronic Total Coronary Occlusions With Myocardial Ischemia - ISCHEMIA-CTO Trial","ISCHEMIA-CTO","Inclusion Criteria:\n\n* CTO in native coronary artery\n* Myocardial ischemia in a territory supplied by CTO assessed by nuclear imaging.\n* Age ≥18 yrs.\n* Able to provide written informed consent and willing to comply with the specified follow-up contacts.\n* Target artery ≥ 2.5 mm\n\nPrior to randomization all patients undergo 3 months of OMT. Subsequently the population will be divided into:\n\nCohort A: Asymptomatic (CCS \\\u003C 2 and SAQ QoL \\> 60) patients with myocardial ischemia (≥ 10% of LV) in a territory supplied by CTO\n\nCohort B: Symptomatic patients (CCS class ≥ 2 and\u002For SAQ QoL score ≤ 60 after treating non CTO lesions and after OMT) with Myocardial ischemia (5% of LV) in a territory supplied a CTO assess by nuclear imaging.\n\nCohort C: Screening population not eligible for randomization in cohort A or B\n\nExclusion Criteria:\n\n* NSTEMI or STEMI within 1 month\n* Coronary anatomy not suitable for CTO-procedure\n* Coronary disease involving the left main\u002Fthree vessel disease with indication for CABG following heart team conference.\n* Life expectancy \\\u003C 2 years\n* Severe chronic pulmonary disease (FEV1 \\\u003C 30 % of predicted value)\n* Contraindication to dual anti-platelet therapy\n* Pregnancy\n* eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n* In multi-vessel disease: if it is deemed unsafe to treat the non-CTO lesion first.\n* Severe valvular heart disease",{"count":630,"type":22},1560,[83],"Study design\n\nProspective randomized open labeled multicenter study\n\nHypotheses\n\n1. In asymptomatic patients with ≥ 10% of myocardial ischemia: PCI (Percutaneous Coronary Intervention) with latest generation of drug eluting stents is superior to optimal medical therapy in terms of relative reduction in MACCE (Major Adverse Cardiovascular and Cerebrovascular events).\n2. In symptomatic patients with ≥ 5% of myocardial ischemia: PCI with latest generation of drug eluting stents is superior to optimal medical therapy (OMT) in terms of improved life quality measured as an increase of SAQ (Self Assessment Questionnaire) score of 8 points after 6 months.\n\nInclusion Criteria\n\n* CTO in native coronary artery\n* Myocardial ischemia in a territory supplied by CTO assessed by nuclear imaging.\n* Age ≥18 yrs.\n* Able to provide written Informed consent and willing to comply with the specified follow-up contacts\n* Target artery ≥ 2.5 mm\n\nPrior to randomization all patients undergo 3 months of OMT. Subsequently the population will be divided into:\n\nCohort A: Asymptomatic (CCS \\\u003C 2 and SAQ QoL \\> 60) patients with myocardial ischemia (≥ 10% of LV) in a territory supplied by CTO\n\nCohort B: Symptomatic patients (CCS class ≥ 2 and\u002For SAQ QoL score ≤ 60 after treating non CTO lesions and after OMT) with Myocardial ischemia (5% of LV) in a territory supplied a CTO\n\nCohort C: patients enrolled but not randomized in cohort A or B\n\nExclusion criteria (for both cohort A and B)\n\n* NSTEMI or STEMI within 1 month\n* Coronary anatomy not suitable for CTO-procedure\n* Coronary artery disease involving the left main\u002Fthree-vessel disease with indication for CABG following heart team conference\n* Life expectancy \\\u003C 2 years\n* Severe chronic pulmonary disease (FEV1 \\\u003C 30 % of predicted value)\n* Contraindication to dual anti-platelet therapy\n* Pregnancy\n* eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n* In multi-vessel disease: if it is deemed unsafe to treat the non-CTO lesion first.\n* Severe valvular heart disease\n\nPrimary endpoint\n\nCohort A: Composite endpoint of MACCE (all-cause mortality, stroke, any myocardial infarction, clinically driven revascularization\\*), hospitalization for heart failure or incidence of malignant arrhythmias.\n\n\\*CCS class ≥ 2 and\u002For QoL score \\\u003C 60. Same criteria used as for allocation to Cohort B\n\nCohort B: SAQ Quality of Life Assessment after 6 months.\n\nNumber of patients\n\n1,560 (1200 in cohort A\u002F360 in cohort B\n\nFollow up time\n\nCohort A: 5 years Cohort B: 6 months",[28,634],"Chronic Total Occlusion of Coronary Artery","2025-12-29",{"date":637,"type":36},"2026-01-02",{"date":639,"type":36},"2018-11-06",{"date":641,"type":22},"2032-11-01",{"name":368,"class":43},{"id":644,"slug":645,"hasResults":12,"nctId":646,"briefTitle":647,"officialTitle":648,"acronym":649,"eligibilityCriteria":650,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":651,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":653,"conditions":654,"keywords":655,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":660,"completionDateStruct":662,"leadSponsor":664,"locationsCount":665},"100486709","supraflex-cruz-pmcf-study--repic05--100486709","NCT05617599","SUPRAFLEX CRUZ PMCF Study ( rEpic05 )","SUPRAFLEX CRUZPost-Market Clinical Follow-up Study","Multiflex","Inclusion Criteria:\n\n* ≥ 18 years old and;\n* Patients treated with SUPRAFLEX CRUZ according to routine hospital practice and following instructions for use\n* Patients with multivessel coronary artery disease (understood as that which affects more than one territory of the major epicardial coronary arteries - anterior descending, circumflex, right coronary artery) who is treated with more than 1 stent under study in lesions located in more than 1 of the aforementioned arteries.\n* Substudy: Patients with Ejection Fraction \\\u003C45% by Echocardiography\n* Informed consent signed\n\nExclusion Criteria:\n\n* Not meet inclusion criteria\n* Contraindication for antiplatelet treatment\n* Patient life expectancy less than 12 months",{"count":652,"type":22},508,"Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Medical Device Regulations (MDR) with multivessel coronary disease requirements in all the CONSECUTIVE patients treated with (SUPRAFLEX CRUZ).",[333,28],[656,31],"CE-MDR (Medical Device Regulations)","2025-12-15",{"date":659,"type":36},"2025-12-16",{"date":661,"type":36},"2023-05-10",{"date":663,"type":22},"2026-12-01",{"name":42,"class":43},21]